Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes
Abstract
:1. Introduction
2. Results and Discussion
2.1. Isothermal Titration Calorimetry
2.2. Differential Scanning Calorimetry
2.3. Phase Solubility Study
2.4. FT-IR
2.5. 1HNMR
2.6. MALDI TOF MS
2.7. Hirshfeld Surface Analysis
2.8. Biochemical Analysis
3. Materials and Methods
3.1. Materials
3.2. Methods
3.2.1. Isothermal Titration Calorimetry
3.2.2. Differential Scanning Calorimetry
3.2.3. Phase Solubility Study
3.2.4. FT-IR
3.2.5. 1HNMR
3.2.6. MALDI TOF MS
3.2.7. Hirshfeld Surface Analysis
3.2.8. Biochemical Analysis
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Luo, Y.-R. Comprehensive Handbook of Chemical Bond Energies; CRC Press Taylor & Francis Group: Boca Raton, FL, USA, 2007; ISBN 9780429128684. [Google Scholar]
- Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320–330. [Google Scholar] [CrossRef]
- Shah, P.; Westwell, A.D. The role of fluorine in medicinal chemistry. J. Enzym. Inhib. Med. Chem. 2007, 22, 527–540. [Google Scholar] [CrossRef] [Green Version]
- Knopp, R.H.; Bays, H.; Manion, C.V.; Lipka, L.J.; Melani, L.; LeBeaut, A.P.; Suresh, R.; Veltri, E.P. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atheroscler. Suppl. 2001, 2, 90. [Google Scholar] [CrossRef]
- Phan, A.B.; Dayspring, T.D.; Toth, P.P. Ezetimibe therapy: Mechanism of action and clinical update. Vasc. Health Risk Manag. 2012, 8, 415–427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sudhop, T.; Lütjohann, D.; Kodal, A.; Igel, M.; Tribble, D.L.; Shah, S.; Perevozskaya, I.; von Bergmann, K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106, 1943–1948. [Google Scholar] [CrossRef] [Green Version]
- Frömming, K.-H.; Szejtli, J. Cyclodextrin in Pharmacy; Springer: Dordrecht, The Netherlands, 1994; ISBN 0-7923-2139-1. [Google Scholar]
- Villiers, A. Sur la transformation de la fécule en dextrine par le ferment butyrique. Comptes Rendus De L’académie Des Sci. 1891, 112, 435–438. [Google Scholar]
- Gergely, V.; Sebestyén, G.; Virág, S. Toxicity studies of beta-cyclodextrin. In Proceedings of the First International Symposium on Cyclodextrins, Budapest, Hungary, 30 September–2 October 1981; Springer: Dordrecht, The Netherlands, 1982; pp. 109–113. [Google Scholar]
- Gerloczy, A.; Fonagy, A.; Keresztes, P.; Perlaky, L.; Szejtli, J. Absorption, distribution, excretion and metabolism of universally labelled 14-C-β-Cyclodextrin in rat after per Os administration. Arzneim.-Forsch. Drug Res. 1985, 35, 1042–1047. [Google Scholar]
- Jevprasesphant, R.; Penny, J.; Jalal, R.; Attwood, D.; McKeown, N.B.; D’Emanuele, A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003, 252, 263–266. [Google Scholar] [CrossRef]
- Buczkowski, A.; Waliszewski, D.; Urbaniak, P.; Palecz, B. Study of the interactions of PAMAM G3-NH2 and G3-OH dendrimers with 5-fluorouracil in aqueous solutions. Int. J. Pharm. 2016, 505, 1–13. [Google Scholar] [CrossRef]
- Rekharsky, M.V.; Inoue, Y. Complexation thermodynamics of cyclodextrins. Chem. Rev. 1998, 98, 1875–1918. [Google Scholar] [CrossRef]
- Crini, G. Review: A history of cyclodextrins. Chem. Rev. 2014, 114, 10940–10975. [Google Scholar] [CrossRef]
- Harada, A. Cyclodextrin-based molecular machines. Acc. Chem. Res. 2001, 34, 456–464. [Google Scholar] [CrossRef]
- Gattuso, G.; Gargiulli, C.; Parisi, M. Threading cyclodextrins in chloroform: A [2]Pseudorotaxane. Int. J. Mol. Sci. 2007, 8, 1052–1063. [Google Scholar] [CrossRef] [Green Version]
- Suzaki, Y.; Fujii, Y.; Osakada, K. Cyclodextrin rotaxanes of pt complexes and their conversion to pt nanoparticles. Molecules 2020, 25, 5617. [Google Scholar] [CrossRef] [PubMed]
- Stepniak, A.; Erdenebayar, B.; Biernacka, M.; Buczkowski, A.; Zavodnik, L.; Zavodnik, I.; Palecz, B. Calorimetric studies of α-cyclodextrin inclusion complexes with carbendazim and thiabendazole. Phys. Chem. Liq. 2021, 59, 495–502. [Google Scholar] [CrossRef]
- Buko, V.; Zavodnik, I.; Palecz, B.; Stepniak, A.; Kirko, S.; Shlyahtun, A.; Misiuk, W.; Belonovskaya, E.; Lukivskaya, O.; Naruta, E.; et al. Betulin/2-Hydroxypropyl-β-Cyclodextrin inclusion complex: Physicochemical characterization and hepatoprotective activity. J. Mol. Liq. 2020, 309, 113118. [Google Scholar] [CrossRef]
- Szejtli, J.; Bolla-Pusztai, E.; Szabó, P.; Ferenczy, T. Enhancement of stability and biological effect of cholecalciferol by β-Cyclodextrin complexation. Pharmazie 1980, 35, 779–787. [Google Scholar] [PubMed]
- Yonezawa, Y.; Maruyama, S.; Takagi, K. Stability of inclusion complexes of cyclodextrins with guaiazulene. Agric. Biol. Chem. 1981, 45, 505–506. [Google Scholar] [CrossRef]
- Terauchi, M.; Tamura, A.; Arisaka, Y.; Masuda, H.; Yoda, T.; Yui, N. Cyclodextrin-based supramolecular complexes of osteoinductive agents for dental tissue regeneration. Pharmaceutics 2021, 13, 136. [Google Scholar] [CrossRef] [PubMed]
- Athanassiou, G.; Michaleas, S.; Lada-Chitiroglou, E.; Tsitsa, T.; Antoniadou-Vyza, E. Antimicrobial activity of β-Lactam antibiotics against clinical pathogens after molecular inclusion in several cyclodextrins. A novel approach to bacterial resistance. J. Pharm. Pharmacol. 2010, 55, 291–300. [Google Scholar] [CrossRef]
- Suharyani, I.; Muchtaridi, M.; Mohammed, A.F.A.; Elamin, K.M.; Wathoni, N.; Abdassah, M. α-Mangostin/γ-Cyclodextrin inclusion complex: Formation and thermodynamic study. Polymers 2021, 13, 2890. [Google Scholar] [CrossRef]
- Song, X.; Mensah, N.N.; Wen, Y.; Zhu, J.; Zhang, Z.; Tan, W.S.; Chen, X.; Li, J. β-Cyclodextrin-Polyacrylamide hydrogel for removal of organic micropollutants from water. Molecules 2021, 26, 5031. [Google Scholar] [CrossRef]
- Brewster, M.E.; Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 2007, 59, 645–666. [Google Scholar] [CrossRef]
- Frijlink, H.W.; Visser, J.; Hefting, N.R.; Oosting, R.; Meijer, D.K.F.; Lerk, C.F. The pharmacokinetics of β-Cyclodextrin and hydroxypropyl-β-Cyclodextrin in the rat. Pharm. Res. 1990, 7, 1248–1252. [Google Scholar] [CrossRef] [PubMed]
- Stella, V.J.; He, Q. Cyclodextrins. Toxicol. Pathol. 2008, 36, 30–42. [Google Scholar] [CrossRef]
- Adin, I.; Iustain, C. Novel Crystalline Form of Ezetimibe and Processes for the Preparation Thereof. U.S. Patent 20060234996A1, 19 October 2006. [Google Scholar]
- Higuchi, T.; Connors, K.A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4, 117–212. [Google Scholar]
- Mendhe, A.; Kharwade, R.; Mahajan, U. Dissolution enhancement of poorly water-soluble drug by cyclodextrins inclusion complexation. Int. J. Appl. Pharm. 2016, 8, 60–65. [Google Scholar] [CrossRef]
- Menezes, P.P.; Serafini, M.R.; Santana, B.V.; Nunes, R.S.; Quintans, L.J.; Silva, G.F.; Medeiros, I.A.; Marchioro, M.; Fraga, B.P.; Santos, M.R.V.; et al. Solid-State β-Cyclodextrin complexes containing geraniol. Thermochim. Acta 2012, 548, 45–50. [Google Scholar] [CrossRef]
- Górniak, A.; Czapor-Irzabek, H.; Złocińska, A.; Karolewicz, B. Physicochemical and dissolution properties of ezetimibe–aspirin binary system in development of fixed-dose combinations. J. Therm. Anal. Calorim. 2021, 144, 1219–1227. [Google Scholar] [CrossRef] [Green Version]
- Wei, Y.; Zhang, J.; Memon, A.H.; Liang, H. Molecular model and in vitro antioxidant activity of a water-soluble and stable Phloretin/Hydroxypropyl-β-Cyclodextrin inclusion complex. J. Mol. Liq. 2017, 236, 68–75. [Google Scholar] [CrossRef]
- Patel, R.; Bhimani, D.; Patel, J.; Patel, D. Solid-state characterization and dissolution properties of ezetimibe–cyclodextrins inclusion complexes. J. Incl. Phenom. Macrocycl. Chem. 2008, 60, 241–251. [Google Scholar] [CrossRef]
- Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Spackman, P.R.; Jayatilaka, D.; Spackman, M.A. Crystal Explorer 17; School of Biomedical and Chemical Sciences, University of Western Australia: Crawley, Australia, 2017. [Google Scholar]
- Ravikumar, K.; Sridhar, B. Ezetimibe monohydrate. Acta Crystallogr. Sect. E Struct. Rep. Online 2005, 61, 2907–2909. [Google Scholar] [CrossRef]
- Ramos, A.I.; Braga, T.M.; Silva, P.; Fernandes, J.A.; Ribeiro-Claro, P.; Lopes, M.D.F.S.; Paz, F.A.A.; Braga, S.S. Chloramphenicol·cyclodextrin inclusion compounds: Co-dissolution and mechanochemical preparations and antibacterial action. Cryst. Eng. Comm. 2013, 15, 2822–2834. [Google Scholar] [CrossRef]
- Alhayali, A.; Selo, M.A.; Ehrhardt, C.; Velaga, S. Investigation of supersaturation and in vitro permeation of the poorly water soluble drug ezetimibe. Eur. J. Pharm. Sci. 2018, 117, 147–153. [Google Scholar] [CrossRef]
- Yu, E.P.K.; Bennett, M.R. Mitochondrial DNA damage and atherosclerosis. Trends Endocrinol. Metab. 2014, 25, 481–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hernandez-Mijares, A.; Bañuls, C.; Rovira-Llopis, S.; Diaz-Morales, N.; Escribano-Lopez, I.; de Pablo, C.; Alvarez, A.; Veses, S.; Rocha, M.; Victor, V.M. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia. Atherosclerosis 2016, 247, 40–47. [Google Scholar] [CrossRef]
- Duchen, M.R. Mitochondria in health and disease: Perspectives on a new mitochondrial biology. Mol. Asp. Med. 2004, 25, 365–451. [Google Scholar] [CrossRef]
- Patergnani, S.; Suski, J.M.; Agnoletto, C.; Bononi, A.; Bonora, M.; de Marchi, E.; Giorgi, C.; Marchi, S.; Missiroli, S.; Poletti, F.; et al. Calcium signaling around mitochondria associated membranes (MAMs). Cell Commun. Signal. 2011, 9, 19. [Google Scholar] [CrossRef] [Green Version]
- Jonas, E.A.; Porter, G.A.; Beutner, G.; Mnatsakanyan, N.; Alavian, K.N. Cell death disguised: The mitochondrial permeability transition pore as the c-Subunit of the F1FO ATP synthase. Pharmacol. Res. 2015, 99, 382–392. [Google Scholar] [CrossRef] [Green Version]
- Armstrong, J.S.; Yang, H.; Duan, W.; Whiteman, M. Cytochrome Bc1 regulates the mitochondrial permeability transition by two distinct pathways. J. Biol. Chem. 2004, 279, 50420–50428. [Google Scholar] [CrossRef] [Green Version]
- Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: The calcium–apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4, 552–565. [Google Scholar] [CrossRef] [PubMed]
- Kowaltowski, A.J.; Castilho, R.F.; Vercesi, A.E. Mitochondrial permeability transition and oxidative stress. FEBS Lett. 2001, 495, 12–15. [Google Scholar] [CrossRef] [Green Version]
- Groom, C.R.; Bruno, I.J.; Lightfoot, M.P.; Ward, S.C. The Cambridge structural database. Acta Crystallogr. Sect. B Struct. Sci. Cryst. Eng. Mater. 2016, 72, 171–179. [Google Scholar] [CrossRef]
- McKinnon, J.J.; Spackman, M.A.; Mitchell, A.S. Novel tools for visualizing and exploring intermolecular interactions in molecular crystals. Acta Crystallogr. Sect. B Struct. Sci. 2004, 60, 627–668. [Google Scholar] [CrossRef]
- Johnson, D.; Lardy, H. Isolation of liver or kidney mitochondria. In Methods in Enzymology; Academic Press: Cambridge, MA, USA, 1967; Volume 10, pp. 94–96. [Google Scholar]
- Petronilli, V.; Cola, C.; Bernardi, P. Modulation of the mitochondrial cyclosporin a-sensitive permeability transition pore. II. The minimal requirements for pore induction underscore a key role for transmembrane electrical potential, matrix PH, and matrix Ca2+. J. Biol. Chem. 1993, 268, 1011–1016. [Google Scholar] [CrossRef]
- Åkerman, K.E.O.; Wikström, M.K.F. Safranine as a probe of the mitochondrial membrane potential. FEBS Lett. 1976, 68, 191–197. [Google Scholar] [CrossRef] [Green Version]
- Moore, A.L.; Bonner, W.D. Measurements of membrane potentials in plant mitochondria with the safranine method. Plant Physiol. 1982, 70, 1271–1276. [Google Scholar] [CrossRef] [PubMed]
- Buczkowski, A.; Urbaniak, P.; Palecz, B. Thermochemical and spectroscopic studies on the supramolecular complex of PAMAM-NH2 G4 dendrimer and 5-Fluorouracil in aqueous solution. Int. J. Pharm. 2012, 428, 178–182. [Google Scholar] [CrossRef]
αCD | βCD | HPβCD | |
---|---|---|---|
N | 0.85 ± 0.22 | 1.08 ± 0.06 | 0.82 ± 0.25 |
K [dm3 mol−1] | 815 ± 106 | 1710 ± 122 | 2940 ± 266 |
ΔH [J mol−1] | −267.83 ± 80.39 | −641.42 ± 41.03 | −710.92 ± 53.17 |
ΔS [J mol−1 K−1] | 54.85 | 59.87 | 64.06 |
ΔG [kJ mol−1] | −16.24 | −18.03 | −19.35 |
αCD | βCD | HPβCD | SBEβCD | |
---|---|---|---|---|
Increase of solubility 0–15 mM | 4.09 ± 0.27 | 21.20 ± 1.21 | 21.22 ± 0.68 | 26.12 ± 0.71 |
Increase of solubility 0–90 mM | 13.07± 0.60 | 142.41 ± 2.88 | 214.19 ± 5.25 | |
K [dm3 mol−1] | 125.20 ± 6.74 | 1324.37 ± 130.70 | 1580.06 ± 42.27 | 2346.6 ± 85.46 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Biernacka, M.; Ilyich, T.; Zavodnik, I.; Pałecz, B.; Stepniak, A. Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes. Int. J. Mol. Sci. 2022, 23, 455. https://doi.org/10.3390/ijms23010455
Biernacka M, Ilyich T, Zavodnik I, Pałecz B, Stepniak A. Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes. International Journal of Molecular Sciences. 2022; 23(1):455. https://doi.org/10.3390/ijms23010455
Chicago/Turabian StyleBiernacka, Marta, Tatsiana Ilyich, Ilya Zavodnik, Bartłomiej Pałecz, and Artur Stepniak. 2022. "Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes" International Journal of Molecular Sciences 23, no. 1: 455. https://doi.org/10.3390/ijms23010455